ESCRS - PP23.08 - Evaluation Of Dry Eye Signs And Symptoms And Patient Satisfaction After 84 Days Of Treatment With Preservative-Free Eye Drops Containing Sodium Hyaluronate And Trehalose

Evaluation Of Dry Eye Signs And Symptoms And Patient Satisfaction After 84 Days Of Treatment With Preservative-Free Eye Drops Containing Sodium Hyaluronate And Trehalose

Published 2022 - 40th Congress of the ESCRS

Reference: PP23.08 | Type: ESCRS 2022 - Posters | DOI: 10.82333/qtqk-cp12

Authors: Antonio J Mateo-Orobia 1 , Alejandro Blasco-Martínez 2 , Eduardo Del-Prado-Sanz 2 , Sarah Farrant 3 , Miriam Idoipe Costa* 4

1Ophthalmology ,Miguel Servet Universitary Hospital,Zaragoza,Spain, 2Ophthalmology,Miguel Servet Universitary Hospital,Zaragoza,Spain, 3Earlam and Christopher Optometrists and Contact Lens Specialists,Tauton,United Kingdom, 4Ophthalmology,Miguel Servet Universitary Hospital,Zaragossa,Spain

Purpose

Dry eye disease (DED) is characterized by ocular discomfort and visual disturbance. It has a multifactorial etiology, including insufficient tear production and/ or excessive tear evaporation linked to multiple conditions.

A preservative-free eye drop formulation containing sodium hyaluronate and trehalose (SH-THL, Thealoz® Duo, Laboratoires Théa, France) capitalizes on the bioprotectant properties of trehalose.

This study evaluated, after 21 and 84 days of daily use, the improvement of ocular surface disease (OSD), dry eye signs and symptoms, treatment satisfaction in patients with DED receiving SH-THL.

Setting

Multicentre, non-interventional, prospective, international survey conducted in 20 ophthalmological practices in Spain and in 10 optometrist centres in the United Kingdom.

Methods

This survey lasted 84 days with up to 2 post-baseline visits in up to 310 adult subjects, either previously treated either naïve patient, with clinically confirmed DED requiring artificial tears. Clinical signs with Schirmer Test, tear Break Up Time, Oxford score, conjunctival hyperemia, dry eye symptoms with the Ocular Surface Disease Index (OSDI®) and the Dry Eye Questionnaire (DEQ-5) as well as patient satisfaction were assessed at baseline, visit 1 (28 days) and 2 (84 days). SH-THL was to be instilled when needed.

Results

82.4% were women, the mean age was 57.9±15.2 years. 49.7% patients enrolled were naïve patients. At baseline, the overall OSDI was 41.7±20.6 and 60.3% of patients had severe OSDI. The DEQ-5 score was 12.3±4.2 and the patient treatment satisfaction score was 6.4±2.1.

The OSDI significantly improved (p<0.001) after 84 days. From the 148 patients with severe OSDI at baseline, 44.6% had at visit 2 either normal or mild or moderate OSDI. The DEQ-5 score and patient satisfaction significantly improved after 84 days compared to baseline (p<0.001 for both). All clinical signs significantly improved after 84 days of SH-THL in the worse eye (p<0.001) for all patients and also for naïve patients only (all tests p<0.001 except Schirmer test p=0.022).

Conclusions

Results confirm that continued use of eye drops containing sodium hyaluronate and trehalose improved significantly DED signs and symptoms and patient satisfaction in naïve patients and patients previously treated with artificial tears.